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We analyzed human papillomavirus (HPV) prevalences 
during prevaccination and postvaccination periods to con-
sider possible changes in nonvaccine HPV genotypes af-
ter introduction of vaccines that confer protection against 
2 high-risk types, HPV16 and HPV18. Our meta-analysis 
included 9 studies with data for 13,886 girls and women ≤19 
years of age and 23,340 women 20–24 years of age. We 
found evidence of cross-protection for HPV31 among the 
younger age group after vaccine introduction but little evi-
dence for reductions of HPV33 and HPV45. For the group 
this same age group, we also found slight increases in 2 
nonvaccine high-risk HPV types (HPV39 and HPV52) and 
in 2 possible high-risk types (HPV53 and HPV73). However, 
results between age groups and vaccines used were incon-
sistent, and the increases had possible alternative explana-
tions; consequently, these data provided no clear evidence 
for type replacement. Continued monitoring of these HPV 
genotypes is important.
Persistent infection with a high-risk human papillo-mavirus (HPV) genotype is necessary for develop-
ment of cervical cancer (1). Two high-risk types, HPV16 
and HPV18, cause ≈70%–80% of cervical cancers (2–4). 
The HPV vaccines currently available commercially have 
been shown in trial settings to have ≈100% vaccine effi-
cacy against cervical disease caused by vaccine-specific 
high-risk HPV types: bivalent and quadrivalent vaccines 
against HPV16 and HPV18 and the new nonavalent vac-
cine against HPV31, HPV33, HPV45, HPV52, and HPV58 
(5–7). Clinical trial data for the bivalent and quadrivalent 
vaccines have shown low-to-moderate protection (i.e., 
cross-protection) against other high-risk HPV types that 
are phylogenetically related to HPV16 and HPV18 (8,9).
Many countries have now introduced HPV vaccination 
programs (10). A recently published systematic review and 
meta-analysis assessed population-level effects of HPV 
vaccination on vaccine HPV types and showed strong evi-
dence that HPV vaccination is highly effective against in-
fections with these vaccine-specific high-risk types (11). 
The review also examined closely related HPV types as a 
single group and found evidence of cross-protection over-
all in a population-based setting (11). However, assess-
ment of changes in the prevalence of closely related HPV 
types combined may not provide full evidence of the ef-
fects of a national vaccination program because examining 
the types as a single group potentially conceals decreases 
or increases in the prevalence of individual types. Group-
ing HPV types together limits the possibility of examining 
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 Effects of HPV Vaccination on Nonvaccine Genotypes
cross-protection provided by specific HPV types and of de-
tecting changes in other individual nonvaccine types. For 
example, a theoretical concern is that reduced prevalences 
of infection with HPV16 and HPV18 could lead to other 
high-risk HPV types occupying those niches and becoming 
more common causes of disease. Although type replace-
ment was not observed in the clinical trials (12), moni-
toring for possible type replacement in population-based 
settings after the introduction of national HPV vaccination 
programs is important. Furthermore, because nonvaccine 
HPV types are far less common than vaccine HPV types, a 
single study may have limited scope to determine whether 
type replacement has occurred. Combining data from sev-
eral reports improves the ability to investigate type replace-
ment. We aimed to investigate population-level effects of 
HPV vaccination programs that used bivalent or quadri-
valent vaccines on type-specific prevalences of infection 
caused by individual nonvaccine high-risk HPV types.
Methods
Objectives
Using data from surveys conducted before an HPV vacci-
nation program was introduced and data from surveys after 
the program was introduced, we compared HPV prevalenc-
es for similar populations within the same country. We con-
ducted a systematic literature search to determine changes 
in HPV prevalence for each nonvaccine high-risk HPV 
type. At the time of our search, any eligible study would 
have considered vaccination that used bivalent or quadri-
valent vaccines; consequently, high-risk HPV types used 
only in the nonavalent vaccine were considered nonvaccine 
HPV types. Each individual type was presented separately 
in our analysis. We included HPV types for which some 
cross-protection had been demonstrated in clinical trials 
(HPV31 and HPV33, which are phylogenetically related 
to HPV16, and HPV45, which is phylogenetically related 
to HPV18) (8,9,13); other high-risk HPV types included in 
the nonavalent vaccine (HPV52 and HPV58); other high-
risk and probably high-risk HPV types (HPV35, HPV39, 
HPV51, HPV56, HPV59, and HPV68); and other possibly 
high-risk HPV types (HPV26, HPV53, HPV70, HPV73, 
and HPV82), as classified by the International Agency 
for Research on Cancer (14). This systematic review and 
meta-analysis was reported in accordance with PRISMA 
guidelines (15).
Search Strategy and Selection Criteria
Using Embase, Medline, LILACS, and African Index Me-
dicus databases, we searched for eligible publications pub-
lished from 2007, the year that the first HPV vaccination 
programs were introduced, through February 19, 2016. To 
identify relevant studies that mentioned both vaccination 
and HPV infection or a related disease (such as HPV-re-
lated precancerous lesions, cancers, and genital warts), the 
search strategy incorporated MeSH terms from the PubMed 
database (http://www.ncbi.nlm.nih.gov/mesh) and relevant 
words found in the title or abstract (online Technical Ap-
pendix, http://wwwnc.cdc.gov/EID/article/22/10/16-0675-
Techapp1.pdf). The search had no language restrictions.
Eligible studies were those that assessed population-
level effects of HPV vaccination over time by comparing 
the prevalence of HPV infection (defined by the detection 
of HPV DNA in patient samples) during a prevaccination 
period with the prevalence during a postvaccination period. 
We excluded studies comparing HPV infection in vaccinat-
ed persons with HPV infection in unvaccinated persons as 
part of an individually randomized trial because such stud-
ies would not measure population-level effects. Similarly, 
we excluded studies in which HPV infection was compared 
only between unvaccinated and vaccinated persons in the 
postvaccination period. We also excluded studies in which 
only a small proportion (<2%) of the postvaccination study 
population was vaccinated (i.e., studies conducted in large-
ly unvaccinated populations). One author (D.M.) initially 
reviewed titles and abstracts of studies for eligibility; we 
reviewed in full those studies that appeared to address 
changes in HPV prevalence after introduction of HPV vac-
cination programs. We also compared search results with 
those identified in a recent related review (11), which com-
pared prevaccination and postvaccination periods for high-
risk vaccine types (HPV16 and HPV18), cross-protected 
types (HPV31, HPV33, and HPV45), and all high-risk 
HPV nonvaccine types combined.
Data Extraction and Data Quality
For each study, we extracted data on study design and 
country of study. Then, for both prevaccincation and post-
vaccination periods, we extracted data on year(s) of sample 
collection, study setting and population, sample size, speci-
men type, assay used for HPV DNA testing, HPV geno-
types included in the assay, demographic and sexual behav-
ior data collected, and the measure of effect (and method 
used to determine any effect). For the postvaccination pe-
riod, we also extracted data on the method used to ascertain 
estimated vaccination coverage.
In addition, we assessed the potential bias in each 
study by considering the comparability of the study popula-
tions in the prevaccination versus postvaccination periods 
(i.e., similar setting and population demographics); the ex-
tent of adjustment for potential confounders; the suitability 
of the specimen type to assess HPV DNA infection; the 
suitability of the assay used for accurate HPV DNA testing 
(and whether the suitability of assays differed between the 
prevaccination and postvaccination periods); and the meth-
od used to estimate HPV vaccination coverage. To assess 
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 10, October 2016 1733
SYNOPSIS
external validity, we considered whether the study samples 
were population based. Each of these factors was scored as 
either low risk or high risk.
When published data on HPV prevalence and preva-
lence ratios (PRs) for individual high-risk HPV types 
were unavailable, we contacted authors to request the 
HPV type-specific prevalences during the prevaccina-
tion and postvaccination periods and the PRs for the 2 
periods for each nonvaccine high-risk HPV type. We 
requested PRs adjusted for demographic and sexual be-
havior data or the unadjusted PRs if data on confounders 
were unavailable; we calculated unadjusted PRs if au-
thors provided raw data. By using data from a previously 
conducted validation study, 1 study included adjusted 
odds ratios rather than PRs to adjust for the change in 
assay used during the prevaccination and postvaccina-
tion periods (16).
Data Analysis
We used estimates weighted to account for selection pro-
cesses if that data were available from authors unweighted 
numbers, as shown in online Technical Appendix Table 1). 
We also stratified data by age group (i.e., <19 and 20–24 
years of age) because of expected lower rates of vaccina-
tion coverage and lower vaccine effectiveness in those 
vaccinated at older ages. Consequently, for each study, 
we requested data from authors for the same 2 age groups. 
One study included data for girls <13 years of age, so we 
requested data restricted to those 16–19 years of age (17).
To enable calculation of a PR for a prevalence of 0 
during either the prevaccination or postvaccination period, 
we used a continuity correction of 0.5. When prevalence 
was 0 for both the prevaccination and postvaccination pe-
riods, we excluded the study from the meta-analysis for 
the relevant age group and HPV type. Results were fur-
ther stratified by type of vaccine used (i.e., bivalent or 
quadrivalent). PRs within each subgroup were combined 
to obtain a summary PR by using a fixed-effects model 
if data were not shown to be heterogeneous; lack of het-
erogeneity was determined by a p value >0.10 calculated 
with the Cochrane Q test or by an I2 value <25% (18). 
Sensitivity analyses were restricted to studies that used 
cervical, vulval, or vaginal swabs as specimen type be-
cause urine samples have lower sensitivity for detecting 
HPV DNA infection (19).
Results
Included Studies
After we eliminated duplications, we identified 4,648 
unique articles in searches from all 4 databases (Figure 
1). An initial search of title and abstracts of these articles 
excluded 4,508 (97.0%) because of ineligibility. For the 
remaining 140 articles, we examined the full text to determine 
compliance with eligibility criteria and identified 10 eli-
gible studies (Figure 1). Of these 10 studies, 1 met all eli-
gibility criteria, but the type-specific PRs were unavailable 
from authors (20). Therefore, we included 9 studies in the 
systematic review and meta-analysis (16,17,21–27). All 
eligible studies were repeat cross-sectional studies that 
compared changes in prevalence in populations before 
and after introduction of a national HPV vaccination pro-
gram (online Technical Appendix Table 1). Because only 
1 study considered changes in HPV infection among male 
and female populations, we considered only female popula-
tions in the analysis. Two studies were population-based 
national surveys (23,26); 3 studies were conducted among 
young women obtaining chlamydia screening (16,17,27); 2 
studies comprised young women attending a primary care 
clinic, community health center, or hospital-based adoles-
cent clinic (21,22); and 2 studies comprised women obtain-
ing cervical screening (24,25) (online Technical Appendix 
Table 1). The included studies contained data on 13,886 
girls and women <19 years of age and 23,340 women 20–
24 years of age.
The studies varied in methodologic quality on the basis 
of potential bias (Table 1). Most studies collected some de-
mographic and sexual behavior data to enable appropriate 
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Figure 1. Flowchart for eligible studies included in systematic 
review and meta-analysis of changes in prevalences of 
nonvaccine human papillomavirus (HPV) genotypes after 
introduction of HPV vaccination. *100% title match, author’s 
surname and initial, publication year, and periodical; †85% title 
match, and author surname; ‡includes studies in which the vast 
majority of the population were unvaccinated. RCT, randomized 
controlled trials.
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adjustment of the relative risks, although the number of 
factors collected was limited in some studies (16,17,24,25) 
(Table 1; online Technical Appendix Table 1). 
HPV Types Included in Nonavalent HPV Vaccines 
HPV Types with Prior Evidence for Cross-Protection 
We found evidence of reduced prevalence of HPV31 (Fig-
ure 2; Table 2) among girls and women <19 years of age 
(PR 0.73, 95% CI 0.58–0.91) but found little evidence of 
changed prevalences for HPV33 or HPV45 among this age 
group (PR 1.04, 95% CI 0.78–1.38 for HPV33; PR 0.96, 
95% CI 0.75–1.23 for HPV45). Results were heteroge-
neous for HPV31, HPV33, and HPV45 in women 20–24 
years of age; consequently, we did not calculate summary 
PRs (Figure 2; Table 2).
Other HPV Types 
We found evidence of increased prevalence of HPV52 in 
those <19 years of age (PR 1.34, 95% CI 1.13–1.59) (Figure 
3; Table 2), but because of heterogeneity, we did not calcu-
late summary PRs for those 20–24 years of age. We found 
no evidence of a changed prevalence for HPV58 among the 
younger age group (PR 1.01, 95% CI 0.80–1.26) but found 
borderline evidence of an increase for those 20–24 years of 
age (PR 1.14, 95% CI 0.99–1.31).
Other High-Risk and Possibly High-Risk HPV Types
No consistent patterns appeared across the studies for oth-
er HPV vaccine types not used in the nonavalent vaccine 
(Table 2; online Technical Appendix Figure 1). We found 
evidence of increased prevalences from the prevaccination 
period to the postvaccination period in those <19 years 
of age for HPV39 (PR 1.27, 95% CI 1.05–1.54), HPV53 
(PR 1.51, 95% CI 1.10–2.06), and HPV73 (PR 1.36, 95% 
CI 1.03–1.80). For women 20–24 years of age, evidence 
indicated increased prevalence for HPV39 (PR 1.13, 95% 
CI 1.00–1.28).
Sensitivity Analysis
As a sensitivity analysis, we performed 3 additional analy-
ses, all stratified by age group: by type of vaccine used (i.e., 
bivalent or quadrivalent); by potential bias of the original 
study (i.e., relatively low potential bias, defined as <3 fac-
tors indicating high risk of bias; or relatively high potential 
bias, defined >3 factors indicating high risk of bias) (Ta-
ble 1); and by vaccination coverage (i.e., low <50%; high 
>50%). For studies in settings that used the bivalent vac-
cine, we found evidence of increased prevalence between 
the prevaccination period and postvaccination periods 
among those <19 years of age for HPV52, HPV53, HPV56, 
and HPV70 (online Technical Appendix Table 2, Figures 
2–4). Prevalence of HPV53 among women 20–24 years of 
age also increased. For the quadrivalent vaccine, evidence 
showed increased prevalences of HPV39, HPV51, and 
HPV59 for those <19 years of age. Among those 20–24 
years of age, evidence indicated increased prevalence of 
HPV52 and HPV70 (online Technical Appendix Table 2, 
Figures 2–4).
Many of our analyses that were stratified by potential 
bias of the included studies had results similar to those in 
the unstratified analyses (online Technical Appendix Ta-
ble 3). However, among those <19 years of age, studies 
with a relatively low potential bias showed no evidence of 
increased prevalence for HPV52 or HPV39, although evi-
dence existed when the studies were unstratified. For stud-
ies with relatively high potential bias, among this younger 
age group, evidence showed increased prevalences of 
HPV51 and HPV70, although these increases were not 
present in the unstratified analysis. In women 20–24 years 
of age, evidence showed decreased prevalence for HPV33 
in those studies with a relatively low potential bias. No 
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Table 1. Potential bias and external validity of studies included in meta-analysis of changes in prevalences of nonvaccine HPV 
genotypes* 
Potential bias factors  
Study, authors (reference no.) 
Mesher et 
al. (16)  
Söderlund-
Strand et 
al. (17) 
Cummings 
et al. (21) 
Kahn et 
al. (22) 
Sonnenberg 
et al. (23) 
Tabrizi et 
al. (24) 
Cameron 
et al. (25) 
Markowitz 
et al. (26) 
Chow 
et al. 
(27) 
Population-based 
samples† 
H H H H L L L L H 
Comparative populations† H H L L L L L L H 
Risk factor data collected 
and adjusted for 
H H L L L H H L L 
Samples suitable for 
assessing HPV  
L L L L H L L L L 
Assay with suitable 
accuracy 
L L L L L L L L L 
Identical HPV assays† H L L L L L L L L 
Vaccination status 
collected 
H H L L H L L H H 
*HPV, human papillomavirus; H (in bold), high risk of bias; L, low risk of bias. 
†For both prevaccination and postvaccination periods. 
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summary estimate was provided in the unstratified analy-
sis because of heterogeneity of data. Studies with a rela-
tively high potential bias showed evidence of increased 
prevalences of HPV52 and HPV58 among women 20–24 
years of age. Among this older age group, evidence ex-
isted for decreased prevalence of HPV82 in those studies 
with both relatively high potential bias and relatively low 
potential bias, although those studies with relatively high 
potential bias had a larger decrease. Again, no summary 
estimate was provided in the unstratified analysis because 
of heterogeneity.
Vaccination coverage was high for the younger age 
group in all studies (online Technical Appendix Table 4). 
For the older age group, studies with high vaccination cov-
erage showed decreased prevalence for HPV31. No sum-
mary estimate was provided for the unstratified analysis 
because of heterogeneity. For the older age group, we 
found evidence of increased prevalences for HPV39 and 
HPV58 (similar to results from the unstratified analysis) 
but only in studies with low vaccination coverage. Al-
though not seen in the unstratified analysis, we also found 
evidence of an increased prevalence for HPV70 in low-
coverage studies and borderline evidence of an increased 
prevalence for HPV26 in high-coverage studies. No sum-
mary estimates were provided for the unstratified analyses 
because of heterogeneity.
Discussion
Comprehensive postvaccination surveillance should not 
only consider reductions of vaccine type–specific infec-
tion and associated disease but should also assess any other 
potential effects of reductions of targeted infections. We 
assessed changes in nonvaccine HPV types to determine 
evidence of cross-protection for individual HPV types 
and to investigate the potential concern that reductions in 
certain HPV types after the introduction of HPV vaccina-
tion in a population could create a niche that enables other 
nonvaccine high-risk HPV types to become more common 
(i.e., type replacement). We found evidence of a reduction 
in the prevalence of HPV31 among girls and women <19 
years of age. Our main analysis showed increases in other 
nonvaccine HPV types (HPV39, HPV52, HPV53, HPV58, 
and HPV73), but these increases were inconsistent for the 
2 age groups examined and the vaccines used.
A previous systematic review evaluated changes in 
high-risk HPV types combined and found evidence of a 
reduction in the prevalence of HPV types closely related 
to vaccine types (HPV31, HPV33, and HPV45) when 
they were considered as a single group (PR 0.72, 95% 
CI 0.54–0.96 for girls and women 13–19 years of age) 
(11). Our review provides evidence of reduced prevalence 
for HPV31 but little evidence of reduced prevalence for 
HPV33 or HPV45.
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Figure 2. Prevalence ratios and 95% CIs for high-risk human 
papillomavirus (HPV) types (HPV31, HPV33, and HPV45) that 
had evidence of cross-protection for girls and women <19 years of 
age and women 20–24 years of age in studies included in a meta-
analysis of changes in prevalences of nonvaccine HPV genotypes 
after introduction of HPV vaccination. A) HPV31; B) HPV33; C) 
HPV45. Percentages in brackets represent vaccination coverage 
(>1 dose) for each study and age group. The size of the gray boxes 
around the plot points indicates the relative weight given to each 
study in the calculation of the summary estimate. The study by 
Cameron et al. (25) is omitted from analyses for the younger age 
group because this study included no data for the group <19 years 
of age. The study by Cummings et al. (21) is omitted from analyses 
for women 20–24 years of age because this study included no data 
for this age group. Pre, prevaccination; post, postvaccination. 
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Comparing HPV prevalence in a prevaccination period 
to prevalence in a similar population in a postvaccination 
period enables consideration of population-level effects 
of HPV vaccination on HPV prevalence. However, these 
repeat cross-sectional study designs have limitations. Al-
though all studies addressed similar populations in the pre-
vaccination and postvaccination periods, these populations 
may have undergone temporal changes that are indepen-
dent of HPV vaccination over time and that possibly affect 
HPV prevalence. For example, increases in diagnoses of 
other sexually transmitted infections have occurred during 
the same period as that of HPV vaccination programs (28). 
Furthermore, incidence of genital warts increased in many 
countries before vaccine introduction (29–31) and has con-
tinued to increase postvaccination in persons ineligible for 
vaccination (11). Such findings suggest that the increases 
we observed in some HPV types are possibly associated 
with broad increases in sexual risk over time. We consid-
ered changes in demographics and sexual behavior for the 
populations over time when information was available, but 
unrecorded population changes or other temporal changes 
affecting the relative proportions of high-risk HPV types 
likely occurred over time (32,33). Also, more geographic 
variation exists in the relative frequency of nonvaccine 
HPV types in populations compared with the prevalence of 
HPV16, which, before the vaccination programs, was the 
most frequent high-risk type observed in almost all popula-
tions (34).
Furthermore, the change in assay used during the pre-
vaccination and postvaccination periods was a potential 
source of bias in 1 study (16), which calculated odds ratios 
(ORs) adjusted for differences in diagnostic accuracy. This 
adjusted OR could not be converted to a PR by using the 
log-binomial model and was included as an OR. However, 
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Table 2. Summary prevalence ratios for meta-analysis of changes in nonvaccine high-risk HPV types among girls and women, by age 
group* 
Population age group, y, and HPVtype No. studies† 
Heterogeneity Prevalence ratio  
(95% CI) I2, % p value 
≤19      
 HPV types in nonavalent vaccine 8    
  HPV31  6.4 0.381 0.73 (0.58–0.91) 
  HPV33  0 0.471 1.04 (0.78–1.38) 
  HPV45  5.5 0.387 0.96 (0.75–1.23) 
  HPV52  24.0 0.238 1.34 (1.13–1.59) 
  HPV58  0 0.727 1.01 (0.80–1.26) 
 Other high-risk HPV types 8    
  HPV35  25.1 0.229 – 
  HPV39  0 0.984 1.27 (1.05–1.54) 
  HPV51  43.6 0.088 – 
  HPV56  74.3 <0.001 – 
  HPV59  66.8 0.004 – 
  HPV68  0 0.690 1.26 (0.88–1.81) 
 Other possibly high-risk HPV types 6    
  HPV26  0 0.478 1.63 (0.84–3.16) 
  HPV53  3.6 0.394 1.51 (1.10–2.06) 
  HPV70  23.6 0.257 1.34 (0.75–2.39) 
  HPV73  0 0.961 1.36 (1.03–1.80) 
  HPV82  49.0 0.081 – 
20–24      
 HPV types in nonavalent vaccine  8    
  HPV31  28.8 0.198 – 
  HPV33  50.9 0.047 – 
  HPV45  64.3 0.007 – 
  HPV52  31.0 0.180 – 
  HPV58  0 0.806 1.14 (0.99–1.31) 
 Other high-risk HPV types 8    
  HPV35  7.9 0.369 1.07 (0.85–1.34) 
  HPV39  0 0.522 1.13 (1.00–1.28) 
  HPV51  49.8 0.052 – 
  HPV56  82.6 <0.001 – 
  HPV59  63.6 0.007 – 
  HPV68  35.6 0.145 – 
 Other possibly high-risk HPV types 6    
  HPV26  44.3 0.110 – 
  HPV53  30.8 0.204 – 
  HPV70  25.1 0.246 – 
  HPV73  59.2 0.032 – 
  HPV82  38.3 0.151 – 
*HPV, human papillomavirus; –, prevalence ratio not calculated because of heterogeneity of data. 
†Number of studies was the same for all HPV types within each category. 
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given the low prevalence of individual HPV types, the use 
of an OR instead of a PR for this study was unlikely to have 
affected the results substantially.
Another limitation is that the broad-spectrum as-
says used in these studies (and in baseline prevaccination 
evaluations globally) can lack sensitivity for detecting 
individual HPV types when multiple types are present, 
particularly if another HPV type with a higher viral load 
is present. In the postvaccination period, in the absence 
of HPV16 and HPV18, this lack of sensitivity could lead 
to an apparent but artificial increase in nonvaccine types 
because these types were underestimated in the prevac-
cine period because of the predominance of HPV16 or 
HPV18. Studies have shown this potential unmasking ef-
fect (35,36); some increases in nonvaccine types that we 
observed could result from unmasking.
Given the low prevalence of some nonvaccine HPV 
types, assessing changes in prevalence for individual types 
since the introduction of HPV vaccination has been chal-
lenging. By combining data from several studies, we en-
hanced our power to consider changes in individual HPV 
types. However, even with data from 13,886 girls and 
women <19 years of age and 23,340 women 20–24 years of 
age, we still had limited power to consider changes in very 
rare HPV types or to investigate reasons for the heterogene-
ity in findings for some HPV types because of inconsistent 
evidence for increases of specific nonvaccine types be-
tween age groups and the 2 (i.e., bivalent and quadrivalent) 
vaccines. Conversely, type 1 errors can occur with multiple 
testing, so modest evidence for increases should be inter-
preted with caution.
We decided against performing random-effects meta-
analyses in the presence of between-study heterogeneity 
because, in most instances, inconsistency occurred in the 
direction of effect, making a summary estimate (i.e., the 
average value of these opposing effects) uninformative 
(37). Exploring the causes of heterogeneity could provide 
further insight into the reasons for these increases, so we 
performed 3 subgroup analyses by vaccine used, potential 
bias, and vaccine coverage. Results of the stratification by 
potential bias suggested that increased PRs for some HPV 
types may have been reported more often in the studies with 
relatively high potential bias. However, for all 3 subgroup 
sensitivity analyses, the small number of studies in each 
stratum limited the interpretation of the analyses. Similarly, 
we were limited to only 8 studies for each age group and 
had insufficient ability to perform meta-regression analyses 
(because meta-regression should generally not be consid-
ered for <10 studies) (37). As further data accrue, a useful 
future analysis would be exploring the association between 
reductions in the HPV vaccine types and any increases (not 
resulting from unmasking) in nonvaccine HPV types. If in-
creases result from type replacement, then we would expect 
to see increasing prevalences of nonvaccine HPV types as 
prevalences of vaccine HPV types decrease.
Our confirmation of reductions in a cross-protected 
HPV type is encouraging. However, the results of this sys-
tematic review and meta-analysis provide no clear evidence 
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Figure 3. Prevalence ratios and 95% CIs for other high-risk 
human papillomavirus (HPV) types (HPV52 and HPV58) included 
in the nonavalent vaccine for girls and women <19 years of age 
and women 20–24 years of age in studies included in a meta-
analysis of changes in prevalences of nonvaccine HPV genotypes 
after introduction of HPV vaccination. A) HPV52; B) HPV58. 
Percentages in brackets represent vaccination coverage (>1 dose) 
for each study and age group. The sizes of the gray boxes around 
the plot points indicates the relative weight given to each study in 
the calculation of the summary estimate. The study by Cameron et 
al. (25) is omitted from analyses for the younger age group because 
this study included no data for persons <19 years of age. The study 
by Cummings et al. (21) is omitted from analyses for women 20–24 
years of age because the study included no data for this age group. 
Pre, prevaccination; post, postvaccination. 
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for type replacement because the data are unclear about the 
extent to which any observed increases result from other 
temporal changes, changes in the study populations, or an 
unmasking effect of broad spectrum HPV assays. Large-
scale epidemiologic analyses that use various designs have 
not detected evidence of any interactions between high-risk 
types, and the known high evolutionary stability of these 
viruses lessens the risk that type replacement will be a 
problem (38,39).
Most women included in the surveillance studies were 
those vaccinated at older ages (i.e., potentially vaccinated 
after HPV exposure), and some studies included popula-
tions with relatively low coverage, compared with nation-
ally reported vaccination coverage for routine cohorts. 
Future studies should continue to monitor population-lev-
el prevalences of these HPV types. In particular, studies 
should consider populations vaccinated at young ages and 
having high vaccination coverage and, perhaps more im-
portant, should examine the absolute prevalence of cervical 
intraepithelial neoplasia 3 lesions attributed to each high-
risk HPV type.
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